Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03055624 · ClinicalTrials.gov registry record · NA

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

A NA study of Enlarged Prostate With Lower Urinary Tract Symptoms and Prostatic Hyperplasia, Benign, sponsored by University of California, San Diego.

Completed
Registry status
NA
Development phase
9
Enrollment target
1
Study location

NCT03055624 is a NA study of Enlarged Prostate With Lower Urinary Tract Symptoms and Prostatic Hyperplasia, Benign that has completed, run by University of California, San Diego. The registered enrollment target is 9 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03055624, a NA study of Enlarged Prostate With Lower Urinary Tract Symptoms and Prostatic Hyperplasia, Benign, has completed, sponsored by University of California, San Diego.

COMPLETED
Registry status
NA
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

Investigator-initiated study to evaluate the safety and efficacy of prostate artery embolization for the treatment lower urinary tract symptoms in patients with benign prostatic hyperplasia

Interventions

  • DEVICE Embosphere microparticles for prostate artery embolization

Study Locations (1)

California

  • University of California San Diego - San Diego

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2017-03-01
Est. Completion 2019-02-18
Phase NA

Sponsor

University of California, San Diego

775 total trials

What the Registry Record Tells You About NCT03055624

The ClinicalTrials.gov registry entry for NCT03055624 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Enlarged Prostate With Lower Urinary Tract Symptoms appearing as the primary indexed condition, and to 1 intervention - of which Embosphere microparticles for prostate artery embolization is the first listed.

NCT03055624 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03055624 about?

NCT03055624 is a clinical study titled "Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia". Investigator-initiated study to evaluate the safety and efficacy of prostate artery embolization for the treatment lower urinary tract symptoms in patients with benign prostatic hyperplasia

What is the current status of trial NCT03055624?

This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2017-03-01. Estimated completion is 2019-02-18.

What conditions does trial NCT03055624 study?

This clinical trial studies the following conditions: Enlarged Prostate With Lower Urinary Tract Symptoms, Prostatic Hyperplasia, Benign.

What interventions are being tested in trial NCT03055624?

The interventions under investigation include: Embosphere microparticles for prostate artery embolization (DEVICE).

Who is sponsoring clinical trial NCT03055624?

This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03055624 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Enlarged Prostate With Lower Urinary Tract Symptoms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.